Skip to Content

Genetically Modified Immune Cells Have Killed a Patient, Halting Two Cutting-Edge Trials

September 5, 2017

Progress in an area of cancer treatment known as CAR-T therapy has been swift—but it's a life-and-death game. Never has this been more clear than in the past few days.

Late on Monday, the French biotech firm Cellectis announced that its clinical trials involving genetically modified immune cells to treat two different types of cancer had been halted by the FDA after a patient was killed (Cellectis's stock took a beating on the announcement). The trials aimed to prove that a more advanced version of CAR-T, known as "off the shelf" or "universal" CAR-T, could work. The treatment tweaks T cells from a donor to turn them into cancer-killers and then infuses them into a patient.

Some trials of this technology have shown dramatic success, including appearing to cure two infants who had leukemia earlier this year. And Novartis just received FDA approval last week for what might be thought of as first-generation CAR-T therapy, in which a patient's immune cells are removed, modified, and infused back into them.

Off-the-shelf CAR-T works a little differently, using T cells from donors instead of from the patient themselves. If it proves safe and effective, it would be far easier to administer than the personalized version of CAR-T, which is tailor-made for each patient.

Sadly, though, the death in the Cellectis trial is far from the first in the world of CAR-T.

Last year, trials of personalized CAR-T by the biotech firm Juno resulted in a patient death. Researchers made a quick change to the trial and the FDA allowed it to resume, but three more deaths soon followed. As Endpoints observes, that experience may mean that Cellectis will have a hard time restarting its trials until regulators are convinced the company has better prospects for avoiding a tragic outcome. 

Deep Dive


Embracing CX in the metaverse

More than just meeting customers where they are, the metaverse offers opportunities to transform customer experience.

Identity protection is key to metaverse innovation

As immersive experiences in the metaverse become more sophisticated, so does the threat landscape.

The modern enterprise imaging and data value chain

For both patients and providers, intelligent, interoperable, and open workflow solutions will make all the difference.

Scientists have created synthetic mouse embryos with developed brains

The stem-cell-derived embryos could shed new light on the earliest stages of human pregnancy.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.